Leading Sites

Category

Eli Lilly’s BLAZE-1 Selects Aventiv Research in Columbus as Ohioans Investigate Advanced Monoclonal Antibodies Targeting COVID-19

TrialSite recently profiled Columbus, Ohio-based Aventiv Research as the independent trial site organization was selected by Pfizer as a site to participate in the BNT162 COVID-19 vaccine trial program. Now, local media (WSYX/WTTE) reports that the Columbus-based site...

Columbia University Research Returned, Reactivated and Approaching 100% Capacity

Although a significant number of clinical trials conducted at Columbia University’s Irving Medical Center (CUIMC) were put on hold or delayed during the height of the pandemic in the spring, with the late summer Vagelos College of Physicians and Surgeons and other...

Temple University the Latest Academic Medical Center to Plan Ivermectin Trial: Does the Drug Inhibit SARS-CoV-2 Progression?

Temple University goes back to 1884, founded by Baptist Minister Russell Cornwell. Over a century later with over 40,000 students, the university prepares the largest body of professional practitioners in the State of Pennsylvania. The Lewis Katz School of Medicine...

Heroes Step Up: UW Madison Physician the First to Sign up to Participate in AZD1222 Trial at UW Hospital

The University of Wisconsin-Madison (UW Madison) has been selected as one of the first test sites in the country for the large Phase 3 AZD1222 clinical trial, investigating AstraZeneca’s experimental vaccine originally developed by the University of Oxford. Led by...

Salt Lake City’s Foothill Family Clinic Rapidly Enrolls Vaccine Participants for Two Phase 3 Clinical Trials

Thanks to a partnership with J Lewis Research, healthcare provider Foothill Family Clinic in Salt Lake City, Utah, is conducting two Phase 3 clinical trials for COVID-19 vaccine candidates from both Moderna (mRNA-1273) and Pfizer (BioNTech’s BNT 162). The...

New NIH Investigator Network: NIAID Commits $82m to Form Center for Research in Emerging Diseases (CREID)

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, today announced that it has awarded 11 grants with a total first-year value of approximately $17 million to establish the Centers for Research in Emerging...

University of Illinois Chicago Gears up to Recruit up to 1,000 Diverse Participants for the COVID-19 Vaccine Trial Involving mRNA-1273

The University of Illinois’ Health System launches the COVID-19 vaccine trial testing Moderna’s mRNA-1273 starting this Monday. Led by University of Illinois Chicago, the center targets enrollment of up to 1,000 participants for this clinical trial. Led by Dr. Richard...

Masonic Medical Research Institute Investigating the Connections of COVID-19 to Cardiovascular Conditions

Masonic Medical Research Institute in Utica, New York, now investigates the cardiovascular implications of COVID-19. Led by Dr. Nathan Tucker, Assistant Professor, the research operation sought to better understand why at least some patients infected with SARS-CoV-2,...

Independent Aventiv Research Selected by Pfizer & BioNTech for COVID-19 Vaccine Trial: Volunteers Drive 2 Hours to Contribute

Independently-owned Columbus Ohio-based Aventiv Research was selected by the Pfizer/BioNTech “Project Lightspeed” program to participate in the Phase 2/3 clincial trial to test the RNA-based COVID-19 vaccine. With involvement of 120 sites around the world, this...

Kaiser Permanente Targets 5% of Worldwide Volunteer Enrollment for Project Lightspeed COVID-19 Vaccine Trial

Ranked as the 18th largest healthcare system in the United States, Kaiser Permanente isn’t afraid of ambitious targets as its’ California-based research organizations are no exception, raising the bar by planning to enroll up to 5% of all study participants...

UC Davis Health Ramps Up Project Lightspeed: Serves as Trial Site for Phase 2/3 BNT162 COVID-19 Vaccine Study

UC Davis Health was one of about 120 trial sites selected worldwide to participate in the Phase 2/3 stage testing of the COVID-19 vaccine candidate known as BTN162, developed by Germany’s BioNTech and Pfizer Inc. The addition of this pivotal clinical trial adds even a...

Seres Therapeutics Reports Positive Phase III Data from ECOSPOR III Trial of its Oral Microbiome Therapy SER-109 for Recurrent C. Difficile Infection

Seres Therapeutics reported positive topline results from the pivotal Phase 3 ECOSPOR III study evaluating its investigational oral microbiome therapeutic SER-109 for recurrent C. difficile infection (CDI). The primary endpoint was reached, with SER-109...

Pin It on Pinterest